No article text was recorded for this version.
immune-related adverse events
Version 1 of 138 papers40 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Targeting cytokine and chemokine signaling pathways for cancer therapy
- Blog: Zytokintherapie bei malignen Hauterkrankungen und insbesondere beim malignen Melanom
- Blog: Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022
- Blog: Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives
- Blog: A real-world pharmacovigilance study on cardiovascular adverse events of tisagenlecleucel using machine learning approach
- Blog: Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems
- Blog: New insights on the cardiovascular effects of IGF-1
- Blog: Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
- Blog: POS1567 OUTCOMES AND PREDICTORS OF CHRONIC IMMUNE CHECKPOINT INHIBITOR INDUCED INFLAMMATORY ARTHRITIS: DATA FROM THE CANADIAN RESEARCH GROUP OF RHEUMATOLOGY IN IMMUNO-ONCOLOGY (CANRIO) RETROSPECTIVE COHORT
- Blog: The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
- Blog: 9 A novel humanized mouse model for assessing anti-tumor therapy with anti-human PD-1 and human IL12 bispecific antibody
- Blog: AB1768-HPR SAFETY AND EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH RHEUMATIC AUTOIMMUNE DISEASE: EXPERIENCE FROM THE CANADIAN RESEARCH GROUP OF RHEUMATOLOGY IN IMMUNO-ONCOLOGY (CANRIO)
- Blog: New antibody approaches to lymphoma therapy
- Blog: Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
- Blog: Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma
- Blog: Improving CAR-T cell function through a targeted cytokine delivery system utilizing car target-modified extracellular vesicles
- Blog: Supramolecular Photothermal Nanomedicine Mediated Distant Tumor Inhibition via PD-1 and TIM-3 Blockage
- Blog: Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist
- Blog: POS1361 THE CANADIAN RESEARCH GROUP OF RHEUMATOLOGY IN IMMUNO-ONCOLOGY (CanRIO): A NATIONWIDE MULTI-CENTER PROSPECTIVE COHORT
- Blog: Single-cell RNA sequencing reveals enhanced antitumor immunity after combined application of PD-1 inhibitor and Shenmai injection in non-small cell lung cancer
- Blog: Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
- Blog: Engineered virus-hunter vaccine overcomes HBV immune tolerance
- Blog: PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review
- Blog: A novel approach to inhibit HIV-1 infection and enhance lysis of HIV by a targeted activator of complement
- Blog: Tumor-specific activation of folate receptor beta enables reprogramming of immune cells in the tumor microenvironment
- Blog: Effect of Age on Rheumatic Immune-Related Adverse Events: Experience From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
- Blog: Case report: Cryoablation as a novel bridging strategy prior to CAR-T cell therapy for B cell malignancies with bulky disease
- Blog: The comparison of efficacy and safety between cadonilimab (PD-1/CTLA-4) and anti-PD-1 inhibitors in patients with recurrent or metastatic cervical cancer: a retrospective real-world study
- Blog: 1078 The development of IL15v-NKCE: a cutting-edge NK cell engager platform for cancer treatment
- Blog: Efgartigimod for immune checkpoint inhibitor induced polyradiculoneuropathy and cardiomyopathy: A case report
- Blog: Targeting immune microenvironment in cervical cancer: current research and advances
- Blog: Effectiveness of immunosuppressant use for the treatment of immune checkpoint inhibitor-induced liver injury: A systematic review and meta-analysis
- Blog: CCL4 participates in the reprogramming of glucose metabolism induced by ALV-J infection in chicken macrophages
- Blog: Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets
- Blog: 1388 CRB-601, an integrin αvβ8 blocking antibody entering phase I: pre-clinical and translational biomarkers for indication selection
- Blog: Redirecting immune signaling with cytokine adaptors
- Blog: Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor
- Blog: Immune-related encephalitis after immune checkpoint inhibitor therapy
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_immune_related_adverse_events_6b8402d6,
title = {immune-related adverse events},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/immune-related-adverse-events/rdr_6b8402d60c39456792270b166e7919ad},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}This exact version (version 1, frozen text):
@misc{lacuna_immune_related_adverse_events_6b8402d6_v1,
title = {immune-related adverse events},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/immune-related-adverse-events/rdr_6b8402d60c39456792270b166e7919ad/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}